OVCAS1
MCID: OVR114
MIFTS: 60

Ovarian Cancer 1 (OVCAS1)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Ovarian Cancer 1

MalaCards integrated aliases for Ovarian Cancer 1:

Name: Ovarian Cancer 1 57 29
Ovarian Cancer, Susceptibility to, 1 57 13
Ovarian Cancer, Susceptibility to 57 6
Malignant Neoplasm of Ovary 70
Epithelial Ovarian Cancer 70
Ovarian Carcinoma 70
Ovarian Cancer 57
Ovcas1 57

Classifications:



External Ids:

OMIM® 57 607893
UMLS 70 C0029925 C0677886 C1140680

Summaries for Ovarian Cancer 1

MalaCards based summary : Ovarian Cancer 1, also known as ovarian cancer, susceptibility to, 1, is related to breast-ovarian cancer, familial 2 and papillary serous adenocarcinoma, and has symptoms including pelvic pain An important gene associated with Ovarian Cancer 1 is BRCA1 (BRCA1 DNA Repair Associated), and among its related pathways/superpathways are DNA Double-Strand Break Repair and DNA Damage. The drugs Dexamethasone and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include breast, ovary and t cells, and related phenotypes are Decreased homologous recombination repair frequency and Decreased homologous recombination repair frequency

More information from OMIM: 607893

Related Diseases for Ovarian Cancer 1

Diseases in the Ovarian Cancer family:

Ovarian Cancer 1 Familial Ovarian Cancer

Diseases related to Ovarian Cancer 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 977)
# Related Disease Score Top Affiliating Genes
1 breast-ovarian cancer, familial 2 32.8 BRCA2 BRCA1
2 papillary serous adenocarcinoma 31.6 BRCA2 BRCA1
3 familial ovarian cancer 31.5 RAD51C BRCA2 BRCA1
4 hereditary site-specific ovarian cancer syndrome 31.4 RAD51C BRCA2 BRCA1
5 hereditary breast ovarian cancer syndrome 31.2 RAD51C PALB2 NBN BRCA2 BRCA1
6 primary peritoneal carcinoma 31.1 BRCA2 BRCA1
7 ovary adenocarcinoma 30.9 BRCA2 BRCA1
8 hereditary nonpolyposis colon cancer 30.8 BRCA2 BRCA1
9 ovarian cystadenocarcinoma 30.8 BRCA2 BRCA1
10 fallopian tube carcinoma 30.8 RAD51C PALB2 BRCA2 BRCA1
11 ataxia-telangiectasia 30.5 NBN BRCA2 BRCA1
12 papillary adenocarcinoma 30.4 BRCA2 BRCA1
13 dysgerminoma 30.4 BRCA2 BRCA1
14 lynch syndrome 30.3 RAD51C PALB2 NBN BRCA2 BRCA1
15 breast-ovarian cancer, familial 1 30.3 RAD51C PALB2 NBN BRCA2 BRCA1
16 fanconi anemia, complementation group o 30.3 RAD51C PALB2
17 bilateral breast cancer 30.1 PALB2 BRCA2 BRCA1
18 tetraploidy 30.1 BRCA2 BRCA1
19 endosalpingiosis 30.1 BRCA2 BRCA1
20 uterine corpus cancer 30.0 BRCA2 BRCA1
21 female reproductive endometrioid cancer 30.0 BRCA2 BRCA1
22 female breast cancer 30.0 PALB2 BRCA2 BRCA1
23 hypertrophy of breast 29.9 BRCA2 BRCA1
24 premature menopause 29.7 RAD51C NBN BRCA2 BRCA1
25 li-fraumeni syndrome 29.7 RAD51C PALB2 BRCA2 BRCA1
26 bap1 tumor predisposition syndrome 29.6 PALB2 BRCA2
27 lobular neoplasia 29.6 BRCA2 BRCA1
28 fanconi anemia, complementation group a 29.5 RAD51C PALB2 NBN BRCA2 BRCA1
29 fanconi anemia, complementation group j 29.4 RAD51C PALB2 BRCA2 BRCA1
30 fanconi anemia, complementation group n 29.4 RAD51C PALB2 BRCA2
31 cerebellar disease 29.3 NBN BRCA2 BRCA1
32 fanconi anemia, complementation group q 29.2 RAD51C PALB2
33 fanconi anemia, complementation group p 29.2 RAD51C PALB2
34 sporadic breast cancer 29.1 RAD51C PALB2 NBN BRCA2 BRCA1
35 peritoneum cancer 29.1 RAD51C PALB2 BRCA2 BRCA1
36 islet cell tumor 29.0 PALB2 BRCA2
37 gastric cancer, hereditary diffuse 29.0 RAD51C PALB2 BRCA2 BRCA1
38 medulloblastoma 28.8 PALB2 NBN BRCA2 BRCA1
39 cowden syndrome 28.8 RAD51C PALB2 BRCA2 BRCA1
40 fallopian tube disease 28.6 RAD51C PALB2 BRCA2 BRCA1
41 aplastic anemia 28.2 RAD51C PALB2 NBN BRCA2 BRCA1
42 ovarian cancer 27.1 RAD51C PHF13 PALB2 OVCAS1 NBN FILIP1L
43 ovarian epithelial cancer 11.8
44 breast-ovarian cancer, familial 3 11.6
45 breast-ovarian cancer, familial 4 11.6
46 pancreatic cancer 11.2
47 paraneoplastic cerebellar degeneration 11.1
48 ovarian small cell carcinoma 11.1
49 breast cancer 11.1
50 ovarian disease 11.1

Graphical network of the top 20 diseases related to Ovarian Cancer 1:



Diseases related to Ovarian Cancer 1

Symptoms & Phenotypes for Ovarian Cancer 1

Clinical features from OMIM®:

607893 (Updated 05-Apr-2021)

UMLS symptoms related to Ovarian Cancer 1:


pelvic pain

GenomeRNAi Phenotypes related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased homologous recombination repair frequency GR00151-A-1 10 BRCA1
2 Decreased homologous recombination repair frequency GR00151-A-2 10 BRCA1
3 Decreased homologous recombination repair frequency GR00236-A-1 10 BRCA1 BRCA2 PALB2
4 Decreased homologous recombination repair frequency GR00236-A-2 10 BRCA1 BRCA2 PALB2
5 Decreased homologous recombination repair frequency GR00236-A-3 10 BRCA1 BRCA2 PALB2
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 BRCA1 BRCA2 NBN PALB2
7 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 BRCA1 BRCA2 PALB2
8 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.36 BRCA1 BRCA2 NBN RAD51C
9 Decreased viability with cisplatin GR00101-A-4 9.16 BRCA1 BRCA2
10 Synthetic lethal with cisplatin GR00101-A-1 8.96 BRCA1 BRCA2

MGI Mouse Phenotypes related to Ovarian Cancer 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.43 BRCA1 BRCA2 DPH1 NBN PALB2 RAD51C
2 neoplasm MP:0002006 9.02 BRCA1 BRCA2 DPH1 NBN PALB2

Drugs & Therapeutics for Ovarian Cancer 1

Drugs for Ovarian Cancer 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 488)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
3
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
4
Iron Approved Phase 4 7439-89-6 23925 29936
5
Ferrous fumarate Approved Phase 4 141-01-5
6
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
7 glucocorticoids Phase 4
8 Fibrinolytic Agents Phase 4
9 Antipyretics Phase 4
10 Platelet Aggregation Inhibitors Phase 4
11
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
12
Hydralazine Approved Phase 3 86-54-4 3637
13
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
14
Epirubicin Approved Phase 3 56420-45-2 41867
15
Nintedanib Approved Phase 3 656247-17-5 56843413
16
Amifostine Approved, Investigational Phase 3 20537-88-6 2141
17
Melphalan Approved Phase 3 148-82-3 4053 460612
18
Pertuzumab Approved Phase 3 380610-27-5, 145040-37-5 2540
19
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
20
Treosulfan Approved, Investigational Phase 3 299-75-2 9296
21
Busulfan Approved, Investigational Phase 3 55-98-1 2478
22
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
23
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
24
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
25
tannic acid Approved Phase 3 1401-55-4
26
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
27
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
28
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
29
Procarbazine Approved, Investigational Phase 3 671-16-9 4915
30
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
31
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
32
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
33
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
34
Niraparib Approved, Investigational Phase 3 1038915-60-4 24958200
35
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
36
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
37
Dimethyl sulfoxide Approved, Vet_approved Phase 2, Phase 3 67-68-5 679
38
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
39
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
40
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
41
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
42
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
43
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
44
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
45
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
46
carbamide peroxide Approved Phase 3 124-43-6
47
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
48 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
49
Saracatinib Investigational Phase 2, Phase 3 379231-04-6
50
Farletuzumab Investigational Phase 3 896723-44-7

Interventional clinical trials:

(show top 50) (show all 1663)
# Name Status NCT ID Phase Drugs
1 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
2 Obligatory Post-Registration Open-Label, Non-Comparative Multicenter Study of Efficacy and Tolerance Rate of Caelyx as Monotherapy in Patients With Epithelial Ovarian Cancer, Resistant to Previous Platinum Therapy. Completed NCT00727961 Phase 4 Pegylated Liposomal Doxorubicin hydrochloride
3 Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study Completed NCT02562170 Phase 4
4 A Phase IV Study Comparing the Efficacy of Fosaprepitant to Aprepitant for Chemotherapy Induced Nausea and Vomiting in Patients Treated for Gynecological Cancer Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
5 Diaphragmatic Resection And Gynecological Ovarian Neoplasm Completed NCT03543462 Phase 4
6 Tumor Gene Expression Before and After Intraoperative Dexamethasone in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
7 Tranexamic Acid in Surgery of Advanced Ovarian Cancer - a Prospective Randomized Double Blind Placebo Controlled Study Completed NCT00740116 Phase 4 Tranexamic acid;0.9% NaCl solution
8 The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
9 Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer Recruiting NCT03164980 Phase 4 Trabectidin (Yondelis)
10 Evaluation of PEGylated Doxorubicin Hydrochloride Liposome Injection(Duomeisu®) Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer: A Randomized, Open, Multicenter Clinical Study Recruiting NCT03794778 Phase 4 pegylated liposomal doxorubicin;paclitaxel;Carboplatin
11 An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice Recruiting NCT01932125 Phase 4 Bevacizumab
12 A Clinical Study Investigating Adverse Drug Reactions and Their Biomarker Correlations in Stage IV Cancer Patients Following Individualized Therapy of Apatinib Recruiting NCT03475589 Phase 4 apatinib
13 Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib in Maintenance After Platine-based Chemotherapy for Patients With Ovarian Cancer Late Relapse : the French GINECO - NiQoLe Study Recruiting NCT03752216 Phase 4 Niraparib
14 A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer With Germline BRCA1/2 Mutation Recruiting NCT04330040 Phase 4 Olaparib
15 Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy Recruiting NCT04352439 Phase 4 Aspirin
16 A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS Active, not recruiting NCT01706120 Phase 4 Bevacizumab;Paclitaxel;Carboplatin
17 An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA). Active, not recruiting NCT02476968 Phase 4 Olaparib
18 A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
19 Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment Terminated NCT02035345 Phase 4 Carboplatin
20 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
21 Contrast Enhanced Diffusion-weighted Magnetic Resonance Imaging for Detection of Pathologic Lymph Nodes in Ovarian Cancer - a Feasibility Study. Withdrawn NCT02243059 Phase 4 Gadofosveset trisodium (Ablavar™ )
22 Neoadjuvant Chemotherapy (NACT) Followed by Interval Debulking Surgery vs Upfront Surgery Followed by Chemotherapy (CT) in Advanced Epithelial Ovarian Carcinoma (EOC): A Prospective Randomized Study Unknown status NCT00715286 Phase 3
23 Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel for the Treatment of Patients With Recurrent or Primary Advanced Ovarian Cancer : A Randomised Phase 3 Study Unknown status NCT02681432 Phase 3 HIPEC
24 Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer Unknown status NCT00326456 Phase 3 liposomal doxorubicin;carboplatin;paclitaxel
25 A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
26 Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium Unknown status NCT00004115 Phase 3
27 Evaluating the Effectiveness of Inquiry Based Stress Reduction (IBSR) Intervention Versus Regular Care of no Treatment on Well-being, Optimism and Health Behavior of BRCA1/2 Carriers: A Randomized Controlled Trial, RCT. Unknown status NCT03162276 Phase 3
28 Liposomal Doxorubicin Versus Carboplatin/Paclitaxel in Patients With Ovarian Cancer Recurrence Between 6 and 12 Months After Previous Platinum Based Therapy: Phase III Randomized Multicenter Study Amendment Title Protocol Version 2.0: Phase III International Multicenter Randomized Study Testing the Effect on Survival of Prolonging Platinum-free Interval in Patients With Ovarian Cancer Recurring Between 6 and 12 Months After Previous Platinum Based Chemotherapy. Unknown status NCT00657878 Phase 3 stealth liposomal doxorubicin;carboplatin;paclitaxel;Topotecan;Gemcitabine
29 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
30 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial. Unknown status NCT02328716 Phase 3 Hipec with Cisplatin
31 Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen (e.g., CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully Resected Early Stage Ovarian Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
32 A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer Unknown status NCT01837251 Phase 3 Carboplatin;PLD
33 Feasibility of Intraoperative Given Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin During a Cytoreductive Surgery in Patients With Recurrent Ovarian, Peritoneal or Fallopian Tube Cancers Unknown status NCT03717610 Phase 3
34 An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
35 Randomized, Double-Blind, Phase III Trial of Chemotherapy Plus the Transcriptional Therapy Hydralazine and Magnesium Valproate Versus Chemotherapy Plus Placebo in Cisplatin-Resistant Recurrent Ovarian Cancer. Unknown status NCT00533299 Phase 3 Hydralazine and magnesium valproate;Placebo
36 Phase 2/3 Study of Masitinib in Combination With Gemcitabine Versus Gemcitabine Alone in Advanced/Metastatic Epithelial Ovarian Cancer Patients in Second Line Being Refractory to First Line Platinum Treatment or in Third Line Completed NCT02490488 Phase 2, Phase 3 Masitinib;Gemcitabine;Placebo
37 A Randomized Study of Chemotherapy Versus Hormonal Treatment in Patients With Ovarian Cancer Resistant or Refractory to Platinum and Taxane Completed NCT02728622 Phase 3 Tamoxifen;Chemotherapy
38 A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00866697 Phase 3 Pazopanib;Placebo
39 A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse Completed NCT00849667 Phase 3 MORAb-003 (farletuzumab);MORAb-003 (farletuzumab);0.9% Saline
40 Impact of Exercise on Ovarian Cancer Prognosis Completed NCT02107066 Phase 3
41 Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma Completed NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
42 Randomized Trial of Intraoperative Hyperthermic Intraperitoneal Chemotherapy Followed by Intravenous Chemotherapy in Patients With Ovarian Cancer Completed NCT01091636 Phase 2, Phase 3
43 An Open, Randomized, Multicenter Study in Patients With Recurrent Epithelian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficay and Safety of Paclitaxel (Micellar) Nanoparticles and Paclitaxel (Cremophor® EL) Completed NCT00989131 Phase 3 Paclical®;Taxol®
44 FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Completed NCT02631876 Phase 3 Mirvetuximab soravtansine;Paclitaxel;Pegylated liposomal doxorubicin;Topotecan
45 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
46 A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer Completed NCT00003998 Phase 3 carboplatin;docetaxel;paclitaxel
47 Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
48 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
49 A Multi-National,Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (> 6 Months) Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
50 A Randomised Trial of Interval Debulking Surgery in Epithelial Ovarian Cancer Suboptimally Debulked at Primary Surgery Completed NCT00003695 Phase 3 chemotherapy

Search NIH Clinical Center for Ovarian Cancer 1

Genetic Tests for Ovarian Cancer 1

Genetic tests related to Ovarian Cancer 1:

# Genetic test Affiliating Genes
1 Ovarian Cancer 1 29

Anatomical Context for Ovarian Cancer 1

MalaCards organs/tissues related to Ovarian Cancer 1:

40
Breast, Ovary, T Cells, Prostate, Lymph Node, Bone, Colon

Publications for Ovarian Cancer 1

Articles related to Ovarian Cancer 1:

(show top 50) (show all 589)
# Title Authors PMID Year
1
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. 6
31131967 2019
2
Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. 6
30962250 2019
3
Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation. 6
30765603 2019
4
Usefulness and Limitations of Comprehensive Characterization of mRNA Splicing Profiles in the Definition of the Clinical Relevance of BRCA1/2 Variants of Uncertain Significance. 6
30832263 2019
5
Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil. 6
30606148 2019
6
Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of BRCA1 BRCT Variants on Cancer Risk. 6
30257991 2019
7
Substantial evidence for the clinical significance of missense variant BRCA1 c.5309G>T p.(Gly1770Val). 6
30105462 2018
8
Mechanism for survival of homozygous nonsense mutations in the tumor suppressor gene BRCA1. 6
29712865 2018
9
Homozygous loss of function BRCA1 variant causing a Fanconi-anemia-like phenotype, a clinical report and review of previous patients. 6
29133208 2018
10
A multi-gene panel study in hereditary breast and ovarian cancer in Colombia. 6
28528518 2018
11
The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. 6
28490613 2018
12
Identification of a Novel BRCA1 Pathogenic Mutation in Korean Patients Following Reclassification of BRCA1 and BRCA2 Variants According to the ACMG Standards and Guidelines Using Relevant Ethnic Controls. 6
28111427 2017
13
The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing. 6
28294317 2017
14
Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients. 6
28680148 2017
15
BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. 6
28176296 2017
16
Germline Mutations in PALB2, BRCA1, and RAD51C, Which Regulate DNA Recombination Repair, in Patients With Gastric Cancer. 6
28024868 2017
17
Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2. 6
27616075 2017
18
Two Cases of Carcinosarcomas of the Ovary Involved in Hereditary Cancer Syndromes. 6
27167672 2017
19
Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients. 6
27328445 2016
20
Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. 6
27741520 2016
21
Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil. 6
27914478 2016
22
Earlier Age of Breast Cancer Onset in Israeli BRCA Carriers-Is it a Real Phenomenon? 6
27533489 2016
23
BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population. 6
26833046 2016
24
Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study. 6
27756336 2016
25
Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings. 6
27083775 2016
26
Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. 6
26681312 2016
27
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. 6
27433846 2016
28
Adding In Silico Assessment of Potential Splice Aberration to the Integrated Evaluation of BRCA Gene Unclassified Variants. 6
26913838 2016
29
Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: A monocentric Italian study. 6
27062684 2016
30
BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. 6
26350514 2016
31
Detection of high frequency of mutations in a breast and/or ovarian cancer cohort: implications of embracing a multi-gene panel in molecular diagnosis in India. 6
26911350 2016
32
Functional Assessment of Genetic Variants with Outcomes Adapted to Clinical Decision-Making. 6
27272900 2016
33
Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients. 6
26541979 2016
34
Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. 6
26786923 2016
35
Genetic testing in a cohort of young patients with HER2-amplified breast cancer. 6
26681682 2016
36
Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas. 6
25920394 2016
37
High prevalence of BRCA1 stop mutation c.4183C>T in the Tyrolean population: implications for genetic testing. 6
26014432 2016
38
Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients. 6
26848529 2016
39
Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland. 6
26843898 2016
40
Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. 6
26187060 2016
41
Functional assays provide a robust tool for the clinical annotation of genetic variants of uncertain significance. 6
28781887 2016
42
Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients. 6
27257965 2016
43
Patterns and functional implications of rare germline variants across 12 cancer types. 6
26689913 2015
44
Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer. 6
25971625 2015
45
Germline Mutations of BRCA1 and BRCA2 in Korean Ovarian Cancer Patients: Finding Founder Mutations. 6
26402875 2015
46
Prevalence and differentiation of hereditary breast and ovarian cancers in Japan. 6
24249303 2015
47
Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. 6
26246475 2015
48
Deleterious BRCA1/2 mutations in an urban population of Black women. 6
26250392 2015
49
The role of targeted BRCA1/BRCA2 mutation analysis in hereditary breast/ovarian cancer families of Portuguese ancestry. 6
24916970 2015
50
HBOC multi-gene panel testing: comparison of two sequencing centers. 6
26022348 2015

Variations for Ovarian Cancer 1

ClinVar genetic disease variations for Ovarian Cancer 1:

6 (show top 50) (show all 8347)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BRCA1 NM_007294.4(BRCA1):c.(5193+1_5194-1)_(5277+1_5278-1)del Deletion Pathogenic 983561 GRCh37: 17:41203135-41215349
GRCh38:
2 BRCA2 NM_000059.3(BRCA2):c.5433_5436del (p.Glu1811fs) Deletion Pathogenic 51861 rs397507784 GRCh37: 13:32913924-32913927
GRCh38: 13:32339787-32339790
3 BRCA2 NM_000059.3(BRCA2):c.6070C>T (p.Gln2024Ter) SNV Pathogenic 52000 rs80358844 GRCh37: 13:32914562-32914562
GRCh38: 13:32340425-32340425
4 BRCA2 NM_000059.3(BRCA2):c.6445_6446del (p.Ser2148_Ile2149insTer) Deletion Pathogenic 52100 rs80359592 GRCh37: 13:32914936-32914937
GRCh38: 13:32340799-32340800
5 BRCA2 NM_000059.3(BRCA2):c.4139_4140dup (p.Lys1381fs) Duplication Pathogenic 51605 rs276174842 GRCh37: 13:32912630-32912631
GRCh38: 13:32338493-32338494
6 BRCA2 NM_000059.3(BRCA2):c.4530del (p.Glu1511fs) Deletion Pathogenic 266819 rs886040537 GRCh37: 13:32913020-32913020
GRCh38: 13:32338883-32338883
7 BRCA2 NM_000059.3(BRCA2):c.5291C>G (p.Ser1764Ter) SNV Pathogenic 51837 rs397507778 GRCh37: 13:32913783-32913783
GRCh38: 13:32339646-32339646
8 BRCA2 NM_000059.3(BRCA2):c.775A>T (p.Arg259Ter) SNV Pathogenic 52402 rs397507937 GRCh37: 13:32905149-32905149
GRCh38: 13:32331012-32331012
9 BRCA2 NM_000059.3(BRCA2):c.1528G>T (p.Glu510Ter) SNV Pathogenic 51139 rs80358438 GRCh37: 13:32907143-32907143
GRCh38: 13:32333006-32333006
10 BRCA2 NM_000059.4(BRCA2):c.2372C>G (p.Ser791Ter) SNV Pathogenic 988489 GRCh37: 13:32910864-32910864
GRCh38: 13:32336727-32336727
11 BRCA2 NM_000059.3(BRCA2):c.7303C>T (p.Gln2435Ter) SNV Pathogenic 52305 rs397507910 GRCh37: 13:32929293-32929293
GRCh38: 13:32355156-32355156
12 BRCA2 NM_000059.3(BRCA2):c.8029del (p.Glu2677fs) Deletion Pathogenic 52477 rs80359691 GRCh37: 13:32937367-32937367
GRCh38: 13:32363230-32363230
13 BRCA2 NM_000059.3(BRCA2):c.8175G>A (p.Trp2725Ter) SNV Pathogenic 52519 rs397507965 GRCh37: 13:32937514-32937514
GRCh38: 13:32363377-32363377
14 BRCA2 NM_000059.4(BRCA2):c.8423_8427delinsA (p.Leu2808fs) Indel Pathogenic 1012202 GRCh37: 13:32944630-32944634
GRCh38: 13:32370493-32370497
15 BRCA2 NM_000059.4(BRCA2):c.8487+2T>G SNV Pathogenic 1012203 GRCh37: 13:32944696-32944696
GRCh38: 13:32370559-32370559
16 BRCA2 NM_000059.3(BRCA2):c.8557A>T (p.Lys2853Ter) SNV Pathogenic 372573 rs1057517865 GRCh37: 13:32945162-32945162
GRCh38: 13:32371025-32371025
17 BRCA2 NM_000059.3(BRCA2):c.9286G>T (p.Glu3096Ter) SNV Pathogenic 52806 rs80359199 GRCh37: 13:32968855-32968855
GRCh38: 13:32394718-32394718
18 BRCA2 NM_000059.3(BRCA2):c.9836T>A (p.Leu3279Ter) SNV Pathogenic 267174 rs886040852 GRCh37: 13:32972486-32972486
GRCh38: 13:32398349-32398349
19 BRCA1 NM_007294.4(BRCA1):c.2649_2650insGGCT (p.Thr884fs) Insertion Pathogenic 915315 GRCh37: 17:41244898-41244899
GRCh38: 17:43092881-43092882
20 BRCA1 NM_007294.4(BRCA1):c.1684dup (p.Ile562fs) Duplication Pathogenic 915401 GRCh37: 17:41245863-41245864
GRCh38: 17:43093846-43093847
21 BRCA1 NM_007294.4(BRCA1):c.4064dup (p.Asn1355fs) Duplication Pathogenic 975865 GRCh37: 17:41243483-41243484
GRCh38: 17:43091466-43091467
22 BRCA1 NM_007294.4(BRCA1):c.3307_3308insC (p.Cys1103fs) Insertion Pathogenic 545805 rs1555587988 GRCh37: 17:41244240-41244241
GRCh38: 17:43092223-43092224
23 BRCA1 NM_007294.4(BRCA1):c.190T>G (p.Cys64Gly) SNV Pathogenic 17660 rs80357064 GRCh37: 17:41258495-41258495
GRCh38: 17:43106478-43106478
24 BRCA1 NM_007294.4(BRCA1):c.2292_2293AG[2] (p.Glu765_Ser766insTer) Microsatellite Pathogenic 17666 rs80357780 GRCh37: 17:41245251-41245252
GRCh38: 17:43093234-43093235
25 BRCA1 NM_007294.4(BRCA1):c.3748G>T (p.Glu1250Ter) SNV Pathogenic 17672 rs28897686 GRCh37: 17:41243800-41243800
GRCh38: 17:43091783-43091783
26 BRCA1 NM_007294.3(BRCA1):c.3048_3052dupTGAGA (p.Asn1018Metfs) Duplication Pathogenic 54763 rs80357856 GRCh37: 17:41244495-41244496
GRCh38: 17:43092478-43092479
27 BRCA1 NM_007294.4(BRCA1):c.1016del (p.Lys339fs) Deletion Pathogenic 37386 rs80357569 GRCh37: 17:41246532-41246532
GRCh38: 17:43094515-43094515
28 BRCA1 NM_007294.4(BRCA1):c.1018del (p.Lys339_Val340insTer) Deletion Pathogenic 37387 rs80357774 GRCh37: 17:41246530-41246530
GRCh38: 17:43094513-43094513
29 BRCA1 NM_007294.4(BRCA1):c.1121del (p.Thr374fs) Deletion Pathogenic 37391 rs80357612 GRCh37: 17:41246427-41246427
GRCh38: 17:43094410-43094410
30 BRCA1 NM_007294.4(BRCA1):c.116G>A (p.Cys39Tyr) SNV Pathogenic 37392 rs80357498 GRCh37: 17:41267761-41267761
GRCh38: 17:43115744-43115744
31 BRCA1 NM_007294.4(BRCA1):c.116G>T (p.Cys39Phe) SNV Pathogenic 37393 rs80357498 GRCh37: 17:41267761-41267761
GRCh38: 17:43115744-43115744
32 BRCA1 NM_007294.4(BRCA1):c.2178del (p.Pro727fs) Deletion Pathogenic 872895 GRCh37:
GRCh38:
33 BRCA1 NM_007294.4(BRCA1):c.135-1G>T SNV Pathogenic 37404 rs80358158 GRCh37: 17:41258551-41258551
GRCh38: 17:43106534-43106534
34 BRCA1 NM_007294.4(BRCA1):c.1389_1390delinsG (p.Thr464fs) Indel Pathogenic 37409 rs273897659 GRCh37: 17:41246158-41246159
GRCh38: 17:43094141-43094142
35 BRCA1 NM_007294.4(BRCA1):c.143del (p.Met48fs) Deletion Pathogenic 37412 rs80357637 GRCh37: 17:41258542-41258542
GRCh38: 17:43106525-43106525
36 BRCA1 NM_007294.4(BRCA1):c.1480C>T (p.Gln494Ter) SNV Pathogenic 37415 rs80357010 GRCh37: 17:41246068-41246068
GRCh38: 17:43094051-43094051
37 BRCA1 NM_007294.4(BRCA1):c.1510del (p.Arg504fs) Deletion Pathogenic 37418 rs80357908 GRCh37: 17:41246038-41246038
GRCh38: 17:43094021-43094021
38 BRCA1 NM_007294.4(BRCA1):c.1960A>T (p.Lys654Ter) SNV Pathogenic 37436 rs80357355 GRCh37: 17:41245588-41245588
GRCh38: 17:43093571-43093571
39 BRCA1 NM_007294.4(BRCA1):c.213-11T>G SNV Pathogenic 37449 rs80358061 GRCh37: 17:41256984-41256984
GRCh38: 17:43104967-43104967
40 BRCA1 NM_007294.4(BRCA1):c.213-12A>G SNV Pathogenic 37450 rs80358163 GRCh37: 17:41256985-41256985
GRCh38: 17:43104968-43104968
41 BRCA1 NM_007294.4(BRCA1):c.2138C>G (p.Ser713Ter) SNV Pathogenic 37451 rs80357233 GRCh37: 17:41245410-41245410
GRCh38: 17:43093393-43093393
42 BRCA1 NM_007294.4(BRCA1):c.2105dup (p.Leu702fs) Duplication Pathogenic 37445 rs80357880 GRCh37: 17:41245442-41245443
GRCh38: 17:43093425-43093426
43 BRCA1 NM_007294.4(BRCA1):c.212+1G>A SNV Pathogenic 37446 rs80358042 GRCh37: 17:41258472-41258472
GRCh38: 17:43106455-43106455
44 BRCA1 NM_007294.4(BRCA1):c.2210_2211del (p.Thr737fs) Deletion Pathogenic 37456 rs80357654 GRCh37: 17:41245337-41245338
GRCh38: 17:43093320-43093321
45 BRCA1 NM_007294.4(BRCA1):c.2213_2214dup (p.Lys739fs) Duplication Pathogenic 37457 rs80357574 GRCh37: 17:41245333-41245334
GRCh38: 17:43093316-43093317
46 BRCA1 NM_007294.4(BRCA1):c.2299del (p.Ser767fs) Deletion Pathogenic 37462 rs80357786 GRCh37: 17:41245249-41245249
GRCh38: 17:43093232-43093232
47 BRCA1 NM_007294.4(BRCA1):c.2457del (p.Asp821fs) Deletion Pathogenic 37471 rs80357669 GRCh37: 17:41245091-41245091
GRCh38: 17:43093074-43093074
48 BRCA1 NM_007294.4(BRCA1):c.2515del (p.His839fs) Deletion Pathogenic 37474 rs80357607 GRCh37: 17:41245033-41245033
GRCh38: 17:43093016-43093016
49 BRCA1 NM_007294.4(BRCA1):c.2563C>T (p.Gln855Ter) SNV Pathogenic 37475 rs80357131 GRCh37: 17:41244985-41244985
GRCh38: 17:43092968-43092968
50 BRCA1 NM_007294.4(BRCA1):c.2635G>T (p.Glu879Ter) SNV Pathogenic 37478 rs80357251 GRCh37: 17:41244913-41244913
GRCh38: 17:43092896-43092896

Expression for Ovarian Cancer 1

Search GEO for disease gene expression data for Ovarian Cancer 1.

Pathways for Ovarian Cancer 1

Pathways related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.77 RAD51C PALB2 NBN BRCA2 BRCA1
2 12.12 NBN BRCA2 BRCA1
3
Show member pathways
12.02 RAD51C NBN BRCA2 BRCA1
4
Show member pathways
11.65 RAD51C PALB2 NBN BRCA2 BRCA1
5 11.43 RAD51C PALB2 BRCA2 BRCA1
6
Show member pathways
11.42 NBN BRCA2 BRCA1
7
Show member pathways
11.2 RAD51C PALB2 NBN BRCA2 BRCA1
8 11.1 NBN BRCA1
9 10.9 NBN BRCA1
10 10.78 NBN BRCA1

GO Terms for Ovarian Cancer 1

Cellular components related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.8 RAD51C PHF13 PALB2 NBN DPH1 BRCA2
2 chromosome GO:0005694 9.26 RAD51C NBN BRCA2 BRCA1
3 replication fork GO:0005657 9.16 RAD51C NBN
4 lateral element GO:0000800 8.62 BRCA2 BRCA1

Biological processes related to Ovarian Cancer 1 according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.83 PHF13 NBN BRCA2 BRCA1
2 cell proliferation GO:0008283 9.67 NBN DPH1 BRCA2
3 cellular response to DNA damage stimulus GO:0006974 9.65 RAD51C PALB2 NBN BRCA2 BRCA1
4 DNA repair GO:0006281 9.55 RAD51C PALB2 NBN BRCA2 BRCA1
5 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.54 BRCA2 BRCA1
6 double-strand break repair GO:0006302 9.54 NBN BRCA2 BRCA1
7 male meiosis I GO:0007141 9.51 RAD51C BRCA2
8 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.48 BRCA2 BRCA1
9 DNA double-strand break processing GO:0000729 9.46 NBN BRCA1
10 inner cell mass cell proliferation GO:0001833 9.43 PALB2 BRCA2
11 telomere maintenance via recombination GO:0000722 9.4 RAD51C BRCA2
12 chordate embryonic development GO:0043009 9.32 BRCA2 BRCA1
13 DNA recombination GO:0006310 9.26 RAD51C PALB2 BRCA2 BRCA1
14 double-strand break repair via homologous recombination GO:0000724 9.02 RAD51C PALB2 NBN BRCA2 BRCA1

Sources for Ovarian Cancer 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....